19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co ., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race...
20:19 , Jun 23, 2017 |  BC Extra  |  Clinical News

Novo’s semaglutide shows obesity benefit in Phase II trial

Data from a Phase II study to treat obesity showed subcutaneous semaglutide (NN9535) from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) led to an estimated weight loss benefit of up to 13.8% vs. 2.3% for placebo, combined...
00:41 , Mar 25, 2017 |  BioCentury  |  Strategy

Mountain climbing

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are...
08:00 , Mar 7, 2016 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/4 cls Orexigen Therapeutics Inc. (NASDAQ:OREX) RBC Capital Markets Simos Simeonidis Downgrade Sector performer (from outperform) -28% $0.70 Simeonidis also...
07:00 , Oct 5, 2015 |  BioCentury  |  Finance

Drawn and quartered

There was no joy to be had in 3Q15, as every biotech market cap band fell by at least 15%. After the carnage only one group - companies valued north of $5 billion - are...
07:00 , Sep 14, 2015 |  BioCentury  |  Finance

Gaining leverage

Carl Icahn wants to buy up convertible notes of Vivus Inc. (NASDAQ:VVUS), and if the debt holders agree to his terms the financier would gain a major bargaining chip with the obesity play. Vivus shareholders...
07:00 , Aug 10, 2015 |  BC Week In Review  |  Company News

Vivus endocrine/metabolic news

Vivus will for the second time this year reduce sales representatives for obesity drug Qsymia phentermine/topiramate, this time to 50 from 100. During 1Q15, the company cut the Qsymia sales force down to 100 from...
02:03 , Aug 7, 2015 |  BC Extra  |  Company News

Orexigen amends Contrave deal, reports sales

Orexigen Therapeutics Inc. (NASDAQ:OREX) gained $0.35 to $4.17 on Thursday after amending its Contrave naltrexone / bupropion agreement with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and reporting U.S. sales of the obesity drug. Takeda had sent...
00:01 , Aug 1, 2015 |  BC Extra  |  Company News

Vivus to cut Qsymia sales force

Vivus Inc. (NASDAQ:VVUS) lost $0.22 (13%) to $1.51 after it announced a restructuring plan that will halve from 100 to 50 its sales staff for Qsymia phentermine/topiramate . The company had eliminated another 50 Qsymia...
07:00 , Jul 13, 2015 |  BioCentury  |  Finance

Mid-cap hot streak

Almost all of the biotech market cap tiers tracked by BioCentury ended the second quarter in the black. The lone exception was companies valued below $200 million, which collectively fell a median 1.2%. Big cap...